FIELD: medicine.
SUBSTANCE: invention relates to field of medicine. Claimed is method, including determination of presence or absence of K-rasG12D mutation. Presence of K-rasG12D mutation points to the fact that patient will not respond to treatment with B-Raf inhibitor.
EFFECT: invention provides effective method of identifying patient who does not respond to treatment with B-Raf inhibitor.
6 cl, 34 dwg, 12 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF PI3K INHIBITOR AND MEK INHIBITOR | 2010 |
|
RU2563193C2 |
| BRAF MUTATIONS ENSUING RESISTANCE TO BRAF INHIBITORS | 2011 |
|
RU2571930C2 |
| COMPOSITIONS BASED ON SHP2 INHIBITOR AND METHODS OF CANCER TREATMENT | 2018 |
|
RU2805355C2 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| AGENT INDUCING CELL DEATH FOR CELLS HAVING BRAF GENE MUTATIONS, AGENT SUPPRESSING GROWTH OF SUCH CELLS, AND PHARMACEUTICAL COMPOSITION FOR THE THERAPY OF DISEASES CAUSED BY GROWTH DEFECT OF SUCH CELLS | 2016 |
|
RU2760835C2 |
| PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
| THERAPEUTIC COMPOSITION FOR REDUCING RESISTANCE TO TYROSINE KINASE INHIBITORS | 2016 |
|
RU2735493C2 |
| APOPTOSIS-INDUCING MEANS | 2011 |
|
RU2639459C2 |
| POLYPEPTIDES FOR TREATING ONCOLOGICAL DISEASES | 2017 |
|
RU2728870C2 |
